Abstract |
K-Ras and H-Ras share identical effectors and have similar properties; however, the high degree of tumor-type specificity associated with K-Ras and H-Ras mutations suggests that they have unique roles in oncogenesis. Here, we report that oncogenic K-Ras, but not H-Ras, suppresses non-canonical Wnt/Ca(2+) signaling, an effect that contributes strongly to its tumorigenic properties. K-Ras does this by binding to calmodulin and so reducing CaMKii activity and expression of Fzd8. Restoring Fzd8 in K-Ras mutant pancreatic cells suppresses malignancy, whereas depletion of Fzd8 in H-Ras(V12)-transformed cells enhances their tumor initiating capacity. Interrupting K-Ras- calmodulin binding using genetic means or by treatment with an orally active protein kinase C (PKC)-activator, prostratin, represses tumorigenesis in K-Ras mutant pancreatic cancer cells. These findings provide an alternative way to selectively target this "undruggable" protein.
|
Authors | Man-Tzu Wang, Matthew Holderfield, Jacqueline Galeas, Reyno Delrosario, Minh D To, Allan Balmain, Frank McCormick |
Journal | Cell
(Cell)
Vol. 163
Issue 5
Pg. 1237-1251
(Nov 19 2015)
ISSN: 1097-4172 [Electronic] United States |
PMID | 26590425
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Calmodulin
- Fzd8 protein, human
- KRAS protein, human
- Phorbol Esters
- Receptors, Cell Surface
- prostratin
- HRAS protein, human
- Proto-Oncogene Proteins p21(ras)
|
Topics |
- Amino Acid Sequence
- Animals
- Animals, Genetically Modified
- Calmodulin
(metabolism)
- Cell Line, Tumor
- Disease Models, Animal
- Female
- Genes, ras
- Humans
- Mice
- Molecular Sequence Data
- Pancreatic Neoplasms
(drug therapy, metabolism)
- Papilloma
(metabolism)
- Phorbol Esters
(administration & dosage)
- Phosphorylation
- Protein Binding
(drug effects)
- Proto-Oncogene Proteins p21(ras)
(metabolism)
- Receptors, Cell Surface
(metabolism)
- Wnt Signaling Pathway
|